PortfoliosLab logoPortfoliosLab logo
ACET vs. CRSP
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Performance

ACET vs. CRSP - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Adicet Bio, Inc. (ACET) and CRISPR Therapeutics AG (CRSP). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

ACET vs. CRSP - Yearly Performance Comparison


2026 (YTD)20252024202320222021202020192018
ACET
Adicet Bio, Inc.
-19.12%-45.30%-49.10%-78.86%-48.89%24.48%34.71%-82.71%-48.93%
CRSP
CRISPR Therapeutics AG
-9.29%33.23%-37.12%54.00%-46.36%-50.51%151.39%113.18%-27.58%

Fundamentals

EPS

ACET:

-$19.17

CRSP:

-$5.47

Total Revenue (TTM)

ACET:

$0.00

CRSP:

$36.75M

Gross Profit (TTM)

ACET:

$0.00

CRSP:

-$130.60M

EBITDA (TTM)

ACET:

-$122.11M

CRSP:

-$529.50M

Returns By Period

In the year-to-date period, ACET achieves a -19.12% return, which is significantly lower than CRSP's -9.29% return.


ACET

1D
11.46%
1M
-6.07%
YTD
-19.12%
6M
-47.47%
1Y
-43.63%
3Y*
-58.04%
5Y*
-49.62%
10Y*

CRSP

1D
7.28%
1M
-20.90%
YTD
-9.29%
6M
-26.60%
1Y
39.79%
3Y*
1.70%
5Y*
-16.81%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ACET vs. CRSP — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ACET
ACET Risk / Return Rank: 1919
Overall Rank
ACET Sharpe Ratio Rank: 2020
Sharpe Ratio Rank
ACET Sortino Ratio Rank: 2323
Sortino Ratio Rank
ACET Omega Ratio Rank: 2424
Omega Ratio Rank
ACET Calmar Ratio Rank: 1414
Calmar Ratio Rank
ACET Martin Ratio Rank: 1313
Martin Ratio Rank

CRSP
CRSP Risk / Return Rank: 6161
Overall Rank
CRSP Sharpe Ratio Rank: 6565
Sharpe Ratio Rank
CRSP Sortino Ratio Rank: 6565
Sortino Ratio Rank
CRSP Omega Ratio Rank: 6161
Omega Ratio Rank
CRSP Calmar Ratio Rank: 5858
Calmar Ratio Rank
CRSP Martin Ratio Rank: 5656
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ACET vs. CRSP - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Adicet Bio, Inc. (ACET) and CRISPR Therapeutics AG (CRSP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


ACETCRSPDifference

Sharpe ratio

Return per unit of total volatility

-0.48

0.63

-1.11

Sortino ratio

Return per unit of downside risk

-0.29

1.36

-1.65

Omega ratio

Gain probability vs. loss probability

0.97

1.16

-0.19

Calmar ratio

Return relative to maximum drawdown

-0.77

0.68

-1.45

Martin ratio

Return relative to average drawdown

-1.40

1.35

-2.75

ACET vs. CRSP - Sharpe Ratio Comparison

The current ACET Sharpe Ratio is -0.48, which is lower than the CRSP Sharpe Ratio of 0.63. The chart below compares the historical Sharpe Ratios of ACET and CRSP, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading graphics...

Sharpe Ratios by Period


ACETCRSPDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

-0.48

0.63

-1.11

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.55

-0.28

-0.27

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.53

0.21

-0.74

Correlation

The correlation between ACET and CRSP is 0.32, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Dividends

ACET vs. CRSP - Dividend Comparison

Neither ACET nor CRSP has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

ACET vs. CRSP - Drawdown Comparison

The maximum ACET drawdown since its inception was -99.74%, which is greater than CRSP's maximum drawdown of -85.11%. Use the drawdown chart below to compare losses from any high point for ACET and CRSP.


Loading graphics...

Drawdown Indicators


ACETCRSPDifference

Max Drawdown

Largest peak-to-trough decline

-99.74%

-85.11%

-14.63%

Max Drawdown (1Y)

Largest decline over 1 year

-63.28%

-42.25%

-21.03%

Max Drawdown (5Y)

Largest decline over 5 years

-98.20%

-80.68%

-17.52%

Current Drawdown

Current decline from peak

-99.71%

-77.35%

-22.36%

Average Drawdown

Average peak-to-trough decline

-85.01%

-48.69%

-36.32%

Ulcer Index

Depth and duration of drawdowns from previous peaks

34.83%

21.22%

+13.61%

Volatility

ACET vs. CRSP - Volatility Comparison

Adicet Bio, Inc. (ACET) and CRISPR Therapeutics AG (CRSP) have volatilities of 19.04% and 18.14%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.


Loading graphics...

Volatility by Period


ACETCRSPDifference

Volatility (1M)

Calculated over the trailing 1-month period

19.04%

18.14%

+0.90%

Volatility (6M)

Calculated over the trailing 6-month period

54.00%

44.86%

+9.14%

Volatility (1Y)

Calculated over the trailing 1-year period

91.05%

64.29%

+26.76%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

90.36%

60.36%

+30.00%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

94.13%

64.43%

+29.70%

Financials

ACET vs. CRSP - Financials Comparison

This section allows you to compare key financial metrics between Adicet Bio, Inc. and CRISPR Therapeutics AG. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00200.00M400.00M600.00M800.00M1.00BAprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober0
889.00K
(ACET) Total Revenue
(CRSP) Total Revenue
Values in USD except per share items